News
Public · Published
VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash
VolitionRx made a $500,000 cash partial pre-payment on a $2.4 million convertible note owed to Lind Global Asset Management XII LLC, cutting the remaining principal to $706,667. Its other $7.5 million note was fully repaid in September.
Published:
Updated:
What happened
VolitionRx made a $500,000 cash partial pre-payment on a $2.4 million convertible note owed to Lind Global Asset Management XII LLC, cutting the remaining principal to $706,667. Its other $7.5 million note was fully repaid in September.
Confirmed
Global impact / market context
Paying cash reduces money owed and interest costs, which helps a small company preserve financial flexibility. The waiver also pauses Lind's right to convert debt into shares until January 2027, limiting near-term dilution, which means existing holders keep a larger share of the company.
Analyst inference
VolitionRx is a small, loss-making epigenetics company that has leaned on convertible notes, which are loans that can become shares, for funding. Debt reduction and a conversion pause signal balance-sheet repair, but the company still owes $706,667 and may need more cash.
Analyst inference
What to watch
- Conversion rights are paused until January 1, 2027, unless the closing share price equals or exceeds $0.275, and remaining monthly repayments for 2026 are deferred under the waiver. Confirmed
- Watch whether VolitionRx repays the remaining $706,667 before the pause ends, and whether it raises new money to cover that obligation without adding debt. Proposed
- If the share price reaches $0.275, Lind could convert debt into shares, diluting existing holders. If cash runs low, the company may need new financing, which could raise costs. Analyst inference
Evidence
- Original source link unavailable